by Madaline Spencer | Jul 11, 2025
Surbhi Sidana, MD, Hematologist and Associate Professor at Stanford University, discusses effects of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum...
by Madaline Spencer | Jul 10, 2025
Michael J. Thorpy, MD, Professor of Neurology at Albert Einstein College of Medicine, discusses positive results in study of Lumryz (sodium oxybate) for hallucinations in patients with narcolepsy. Narcolepsy is a chronic neurological disorder...
by Madaline Spencer | Jul 9, 2025
Fadi Fakhouri, MD, PhD, Professor of Nephrology at CHUV Lausanne, Switzerland, discusses new data on pegcetacoplan in patients with C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). C3G is a rare...
by Madaline Spencer | Jul 8, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic (linvoseltamab-gcpt) for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome...
by Madaline Spencer | Jul 8, 2025
Mike Flanagan, PhD, Chief Scientific Officer at Avidity Biosciences, discusses topline results from study testing delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy and the newly initiated phase 3 trial. FSHD is a rare...
